Anticoagulant News and Research

RSS

Hemorrhage risk ‘higher than reported’ for AF warfarin users

Real-world findings for atrial fibrillation patients using warfarin point to a significantly higher risk for hemorrhage than reported for clinical trials.

28 Nov 2012

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

21 Nov 2012

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary.

15 Nov 2012

WU researchers to study blood-clotting disorders

Researchers at Washington University School of Medicine in St. Louis have received a $9 million grant to investigate blood-clotting disorders. From heart attacks and strokes to uncontrolled bleeding, clotting disorders cause more deaths each year in the United States than all types of cancer combined.

7 Nov 2012

Low-dose aspirin effective at preventing serious blood clots

Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the leg or the lungs in patients who have had a previous blood clot a new study shows.

6 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).

29 Oct 2012

UK remains at risk of devastating stroke crisis, new report confirms

The UK remains at risk of a devastating stroke crisis, according to UK health experts launching Reports published today, on World Stroke Day, by Action for Stroke Prevention, an alliance of renowned health experts and patient organisations.

29 Oct 2012

Europe remains at risk of a devastating stroke crisis

Europe remains at risk of a devastating stroke crisis, according to a major new Report, "How Can We Avoid a Stroke Crisis in Europe?" published today, on World Stroke Day, by Action for Stroke Prevention (ASP).

29 Oct 2012

New anti-thrombotic treatments in AF patients can reduce risk of stroke

Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.

29 Oct 2012

SSRI use linked to brain hemorrhage

Use of selective serotonin reuptake inhibitors is associated with an increased risk for brain hemorrhage, particularly intracerebral bleeding, suggest meta-analysis findings.

18 Oct 2012

FDA clears Fenwal's new plasma products

Fenwal Inc., a global leader specializing in separation technologies for blood and cell collection and therapy, announced today it has received clearance from the U.S. Food and Drug Administration for two new indications for collection of plasma products on the Fenwal Alyx and Amicus systems.

8 Oct 2012

Article explores safety and efficacy of aerosol delivery of drugs in ICU patients

Essential medications can be delivered as inhaled drugs to critically ill patients in the Intensive Care Unit (ICU) who require mechanical ventilation to breathe. Aerosol drug delivery is highly complex, however, and if not done properly the medication will not reach the lungs and therapy will be ineffective.

5 Oct 2012

Myocardial infarction mortality rates decrease by 44% over the last 15 years in Argentina

Mortality caused by myocardial infarction has decreased by 44% over the last 15 years in Argentina, according to new research which will be presented during the 38th Argentine Congress of Cardiology.

5 Oct 2012

Novel oral anticoagulant bleeding risk offsets clinical benefit

The use of orally activated Xa antagonist and direct thrombin inhibitors is associated with a significant increase in major bleeding events in acute coronary syndrome patients, a study shows.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation.

24 Sep 2012

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Bristol-Myers Squibb and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that ELIQUIS (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke.

21 Sep 2012

Anticoagulant News and Research

Hemorrhage risk ‘higher than reported’ for AF warfarin users

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

WU researchers to study blood-clotting disorders

Low-dose aspirin effective at preventing serious blood clots

Pradaxa use does not appear to increase serious bleeding

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

UK remains at risk of devastating stroke crisis, new report confirms

Europe remains at risk of a devastating stroke crisis

New anti-thrombotic treatments in AF patients can reduce risk of stroke

SSRI use linked to brain hemorrhage

FDA clears Fenwal's new plasma products

Article explores safety and efficacy of aerosol delivery of drugs in ICU patients

Myocardial infarction mortality rates decrease by 44% over the last 15 years in Argentina

Novel oral anticoagulant bleeding risk offsets clinical benefit

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News